UCLA Medical Center, Los Angeles, California, USA.
J Cardiovasc Electrophysiol. 2010 Jul;21(7):799-803. doi: 10.1111/j.1540-8167.2009.01705.x. Epub 2010 Feb 1.
The Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia (SMASH-VT) trial is the largest randomized trial in substrate-based ablation. We performed a retrospective analysis of patients randomized to prophylactic ablation of ventricular tachycardia to determine the predictive value of clinical and procedural variables on outcomes.
In patients treated with catheter ablation, we examined predictors of ICD-therapy free survival using Cox proportional hazards models. Procedural variables tested included the scar location, number of VT morphologies (VTs) induced, tachycardia cycle length, catheter irrigation, catheter approach, procedural duration, and VT inducibility after ablation. Clinical variables including age, index arrhythmia, NYHA class, ejection fraction, prior revascularization, and baseline medication use were also analyzed.
Among 64 patients randomized to ablation, 61 received the assigned therapy and complete procedural data were available for 54 patients. Thirteen percent (7 of 54) experienced ICD therapies during 2-year follow-up. Patients with subsequent ICD therapies had significantly more VTs induced during the ablation procedure than those without (3.9 +/- 2.1 vs 1.9 +/- 1.8, P = 0.05). The hazard ratio for each additional VT induced was 1.51 (95% CI 1.07-2.13, P = 0.02). Two-year Kaplan-Meier event-free survival rates were 96% for 0-1 VTs induced, and 78% for two or more. The use of irrigated catheters was not predictive of ablation success.
In this small retrospective analysis, the number of VTs induced during the procedure was predictive of 2-year outcomes. This likely reflects a more complex arrhythmia substrate in patients who fail ablation.
基质标测和窦性心律下心室性心动过速消融(SMASH-VT)试验是最大的基于基质的消融随机试验。我们对随机接受预防性消融治疗的患者进行了回顾性分析,以确定临床和程序变量对结果的预测价值。
在接受导管消融治疗的患者中,我们使用 Cox 比例风险模型检查了 ICD 治疗无生存的预测因素。测试的程序变量包括疤痕位置、诱发的室性心动过速形态(VT)数量、心动过速周期长度、导管灌洗、导管入路、程序持续时间和消融后 VT 的可诱导性。还分析了临床变量,包括年龄、指数心律失常、NYHA 分级、射血分数、先前的血运重建和基线药物使用情况。
在随机接受消融治疗的 64 例患者中,有 61 例接受了分配的治疗,有 54 例患者获得了完整的程序数据。在 2 年随访期间,有 13%(7/54)的患者经历了 ICD 治疗。在消融过程中诱发更多 VT 的患者与未诱发 VT 的患者相比,有明显更多的患者经历了 ICD 治疗(3.9 +/- 2.1 比 1.9 +/- 1.8,P = 0.05)。每增加一次诱发 VT 的危险比为 1.51(95% CI 1.07-2.13,P = 0.02)。在诱发 0-1 次 VT 的患者中,2 年 Kaplan-Meier 无事件生存率为 96%,在诱发 2 次或更多次 VT 的患者中为 78%。使用灌洗导管不能预测消融的成功。
在这项小型回顾性分析中,术中诱发 VT 的次数可预测 2 年的结果。这可能反映了在消融失败的患者中存在更复杂的心律失常基质。